Nanoscope Therapeutics Forms Visionary Advisory Committee to Advance Retinal Care
Nanoscope Therapeutics Inc., a clinical-stage biotech pioneering gene-agnostic therapies for retinal degenerative diseases, has launched its Visionary Advisory Committee (VAC). This expert panel brings together leading voices in retina treatment and commercialization to help guide the company’s next phase of growth. The VAC will provide strategic insight across Nanoscope’s scientific, clinical, and community-focused initiatives. With a shared commitment to improving patient outcomes, the committee will play a key role in shaping efforts to bring transformative therapies—beginning with treatments for retinitis pigmentosa (RP) and Stargardt disease (SD)—to the people who need them most.
Nanoscope Therapeutics Forms Visionary Advisory Committee to Advance Retinal Care